BRPI0517398B8 - proteína isolada jak2, sequência nucleotídica, vetor de clonagem e/ou de expressão viral, sondas ou iniciadores, oligonucleotídeo, métodos ex vivo ou in vitro para determinar a presença ou a ausência da variante g1849t do gene jak2, anticorpo monoclonal, hibridoma, kit, sirna, processos in vitro permitindo determinar a inibição específica de jak2 v617f, de triagem, utilização de sirna, e, composição - Google Patents

proteína isolada jak2, sequência nucleotídica, vetor de clonagem e/ou de expressão viral, sondas ou iniciadores, oligonucleotídeo, métodos ex vivo ou in vitro para determinar a presença ou a ausência da variante g1849t do gene jak2, anticorpo monoclonal, hibridoma, kit, sirna, processos in vitro permitindo determinar a inibição específica de jak2 v617f, de triagem, utilização de sirna, e, composição

Info

Publication number: BRPI0517398B8
Authority: BR; Brazil
Prior art keywords: jak2; sirna; variant; absence; vitro
Prior art date: 2004-10-27

Application number

BRPI0517398A

Other languages

English (en)

Portuguese (pt)

Inventor

James Chloé

Le Couedic Jean-Pierre

Casadevall Nicole

Ugo Valérie

Vainchenker William

Original Assignee

Hopitaux Paris Assist Publique

Roussy Inst Gustave

Inst Nat Sante Rech Med

Univ Paris Sud

Univ De Versailles St Quentin En Yvelines

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-27

Filing date

2005-10-26

Publication date

2021-05-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34953071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0517398(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-10-26 Application filed by Hopitaux Paris Assist Publique, Roussy Inst Gustave, Inst Nat Sante Rech Med, Univ Paris Sud, Univ De Versailles St Quentin En Yvelines filed Critical Hopitaux Paris Assist Publique

2008-10-14 Publication of BRPI0517398A publication Critical patent/BRPI0517398A/pt

2021-03-02 Publication of BRPI0517398B1 publication Critical patent/BRPI0517398B1/pt

2021-05-25 Publication of BRPI0517398B8 publication Critical patent/BRPI0517398B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- G01N33/57505—
- G01N33/57595—
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Pathology (AREA)
Plant Pathology (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)

BRPI0517398A 2004-10-27 2005-10-26 proteína isolada jak2, sequência nucleotídica, vetor de clonagem e/ou de expressão viral, sondas ou iniciadores, oligonucleotídeo, métodos ex vivo ou in vitro para determinar a presença ou a ausência da variante g1849t do gene jak2, anticorpo monoclonal, hibridoma, kit, sirna, processos in vitro permitindo determinar a inibição específica de jak2 v617f, de triagem, utilização de sirna, e, composição BRPI0517398B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR0411480A FR2877013A1 (fr)	2004-10-27	2004-10-27	Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
FR0411480		2004-10-27
PCT/EP2005/055586 WO2006045827A1 (fr)	2004-10-27	2005-10-26	Identification d'une mutation de jak2 impliquée dans la polyglobulie de vaquez

Publications (3)

Publication Number	Publication Date
BRPI0517398A BRPI0517398A (pt)	2008-10-14
BRPI0517398B1 BRPI0517398B1 (pt)	2021-03-02
BRPI0517398B8 true BRPI0517398B8 (pt)	2021-05-25

Family

ID=34953071

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0517398A BRPI0517398B8 (pt)	2004-10-27	2005-10-26	proteína isolada jak2, sequência nucleotídica, vetor de clonagem e/ou de expressão viral, sondas ou iniciadores, oligonucleotídeo, métodos ex vivo ou in vitro para determinar a presença ou a ausência da variante g1849t do gene jak2, anticorpo monoclonal, hibridoma, kit, sirna, processos in vitro permitindo determinar a inibição específica de jak2 v617f, de triagem, utilização de sirna, e, composição

Country Status (20)

Country	Link
US (9)	US7781199B2 (de)
EP (2)	EP1692281B8 (de)
JP (3)	JP5090171B2 (de)
KR (1)	KR101203003B1 (de)
CN (1)	CN101072870B (de)
AT (1)	ATE382082T1 (de)
AU (1)	AU2005298636B2 (de)
BR (1)	BRPI0517398B8 (de)
CA (3)	CA2754028A1 (de)
DE (1)	DE602005004008T2 (de)
DK (1)	DK1692281T3 (de)
ES (1)	ES2296229T3 (de)
FR (1)	FR2877013A1 (de)
IL (1)	IL182761A0 (de)
MX (1)	MX2007005174A (de)
PL (1)	PL1692281T3 (de)
PT (1)	PT1692281E (de)
SI (1)	SI1692281T1 (de)
WO (1)	WO2006045827A1 (de)
ZA (1)	ZA200703433B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2877013A1 (fr) *	2004-10-27	2006-04-28	Assist Publ Hopitaux De Paris	Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
CN100497657C (zh) *	2006-09-27	2009-06-10	北京大学人民医院	检测JAK2V617F突变的方法及其专用引物与TaqMan-MGB探针
US20080153097A1 (en) *	2006-11-15	2008-06-26	Eragen Biosciences, Inc.	Methods and kits for detecting jak2 nucleic acid
WO2008153900A1 (en) *	2007-06-06	2008-12-18	University Of Florida Research Foundation	Kinase inhibitor compounds
EP2119796B1 (de) *	2007-07-13	2014-01-15	ARKRAY, Inc.	Sonde zur erkennung von mutationen des jak2-gens und anwendung
GB0820631D0 (en) *	2008-11-11	2008-12-17	London School Hygiene & Tropical Medicine	Vectors
EP2272978B1 (de)	2009-07-10	2012-04-18	Biotrin International Limited	Hochsensibles schnelles isothermisches Verfahren zur Detektion von Punktmutationen und SNPs
WO2011067373A1 (fr) *	2009-12-04	2011-06-09	Assistance Publique - Hopitaux De Paris	Methode de detection d'une polyglobulie chez un chien
AU2011214254B2 (en) *	2010-02-10	2016-06-09	Genon Biotechnologies Oy	Dual activity kinase domains and uses thereof
US20120021413A1 (en) *	2010-04-30	2012-01-26	Arkray, Inc.	Method for Detecting Mutation in Exon 12 of JAK2 Gene, and Nucleic Acid Probe and Kit Therefor
CA2805586C (en) *	2010-07-16	2020-09-01	Stichting Vu-Vumc	A method of analysing a blood sample of a subject for the presence of a disease marker
EP3483607A1 (de)	2011-03-18	2019-05-15	Stichting VUmc	Verfahren zur analyse einer blutprobe einer person auf das vorhandensein eines krankheitsmarkers
JP2013017395A (ja) *	2011-07-07	2013-01-31	Toyobo Co Ltd	骨髄増殖性疾患に関する遺伝子変異を検出するためのプローブおよび該プローブを用いた遺伝子変異の検出方法
GB201116876D0 (en) *	2011-09-30	2011-11-16	Epistem Ltd	Mutational analysis of JAK2
CN103243153B (zh) *	2012-02-10	2014-11-05	复旦大学附属华山医院	Jak2 v617f突变的检测应用
WO2014068072A1 (en)	2012-10-31	2014-05-08	Institut Gustave-Roussy	Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
WO2014072487A1 (en)	2012-11-08	2014-05-15	Centre National De La Recherche Scientifique (Cnrs)	New phosphodeoxyribosyltransferase mutant enzymes and uses thereof
US10106855B2 (en)	2012-11-09	2018-10-23	The Johns Hopkins University	Genetic assay to determine prognosis in Polycythemia Vera patients
US9375485B2 (en)	2012-12-07	2016-06-28	Geron Corporation	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
DK2928477T3 (da)	2012-12-07	2019-10-07	Geron Corp	Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis
WO2014186764A1 (en)	2013-05-16	2014-11-20	Mobelisk Llc	Modular tablet case
WO2016097773A1 (en)	2014-12-19	2016-06-23	Children's Cancer Institute	Therapeutic iap antagonists for treating proliferative disorders
RU2017139122A (ru) *	2015-04-15	2019-05-15	Промедиор, Инк.	Способы лечения миелопролиферативных нарушений
HK1254254A1 (zh)	2015-04-23	2019-07-12	奎斯特诊断投资股份有限公司	用於检测骨髓增殖性疾病中calr突变的方法和组合物
AU2016301380B2 (en) *	2015-08-04	2021-07-01	Acceleron Pharma Inc.	Methods for treating myeloproliferative disorders
CN105441573A (zh) *	2016-01-11	2016-03-30	武汉海吉力生物科技有限公司	用于检测人类jak2基因v617f突变的引物、探针及试剂盒
US20190328857A1 (en) *	2016-06-10	2019-10-31	Io Biotech Aps	Calr and jak2 vaccine compositions
UA127701C2 (uk)	2017-07-28	2023-12-06	Джерон Корпорейшн	Спосіб лікування мієлодиспластичного синдрому (варіанти)
JP7650798B2 (ja)	2018-11-29	2025-03-25	ジェロン・コーポレーション	骨髄異形成症候群を治療する方法
BR112022009598A2 (pt)	2019-11-18	2022-08-16	Janssen Biotech Inc	Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
US11753413B2 (en)	2020-06-19	2023-09-12	Incyte Corporation	Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en)	2020-06-19	2023-07-04	Incyte Corporation	Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en)	2020-07-02	2023-09-26	Incyte Corporation	Tricyclic pyridone compounds as JAK2 V617F inhibitors
EP4620469A3 (de)	2020-07-02	2025-10-01	Incyte Corporation	Tricyclische harnstoffverbindungen als jak2-v617f-hemmer
US11661422B2 (en)	2020-08-27	2023-05-30	Incyte Corporation	Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en)	2020-12-21	2022-06-30	Incyte Corporation	Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es)	2021-02-25	2023-07-05	Incyte Corp	Lactamas espirocíclicas como inhibidores de jak2 v617f
CN119173514A (zh)	2022-03-17	2024-12-20	因赛特公司	作为jak2 v617f抑制剂的三环脲化合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6582908B2 (en) *	1990-12-06	2003-06-24	Affymetrix, Inc.	Oligonucleotides
US5728536A (en)	1993-07-29	1998-03-17	St. Jude Children's Research Hospital	Jak kinases and regulation of Cytokine signal transduction
EP0730663B1 (de)	1993-10-26	2003-09-24	Affymetrix, Inc.	Felder von nukleinsaeuresonden auf biologischen chips
US5753441A (en)	1994-08-12	1998-05-19	Myriad Genetics, Inc.	170-linked breast and ovarian cancer susceptibility gene
US5747282A (en)	1994-08-12	1998-05-05	Myraid Genetics, Inc.	17Q-linked breast and ovarian cancer susceptibility gene
WO1997003358A1 (en)	1995-07-07	1997-01-30	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Method of identifying inhibitors of the jak-stat signal transduction pathway
US5914393A (en) *	1995-12-05	1999-06-22	Incyte Pharmaceuticals, Inc.	Human Jak2 kinase
FI104718B (fi) *	1998-06-18	2000-03-31	Orion Yhtymae Oyj	[[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
US6821724B1 (en)	1998-09-17	2004-11-23	Affymetrix, Inc.	Methods of genetic analysis using nucleic acid arrays
WO2000018960A2 (en)	1998-09-25	2000-04-06	Massachusetts Institute Of Technology	Methods and products related to genotyping and dna analysis
WO2001079555A2 (en)	2000-04-14	2001-10-25	Millennium Pharmaceuticals, Inc.	Roles of jak/stat family members in tolerance induction
CN1440287A (zh) *	2000-06-30	2003-09-03	辉瑞大药厂	治疗外周血管疾病、外周神经病和自主神经病的方法
US20030012788A1 (en)	2000-07-27	2003-01-16	Jean-Christophe Renauld	Method for influencing kinase pathways with IL-22
US20020090622A1 (en)	2000-08-23	2002-07-11	Monisola Adeokun	Chemical compounds
US20050235375A1 (en) *	2001-06-22	2005-10-20	Wenqiong Chen	Transcription factors of cereals
US20060240418A1 (en)	2002-05-03	2006-10-26	Diggans James C	Canine gene microarrays
AU2003256453A1 (en)	2002-07-03	2004-01-23	The Trustees Of Columbia University In The City Of New York	Methods for identifying modulators of mda-7 mediated apoptosis
WO2004020583A2 (en)	2002-08-27	2004-03-11	Bristol-Myers Squibb Company	Polynucleotide predictor set for identifying protein tyrosine kinase modulators
US7537891B2 (en)	2002-08-27	2009-05-26	Bristol-Myers Squibb Company	Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
US20060019284A1 (en)	2004-06-30	2006-01-26	Fei Huang	Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
FR2877013A1 (fr) *	2004-10-27	2006-04-28	Assist Publ Hopitaux De Paris	Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US7514229B2 (en)	2005-09-29	2009-04-07	The Board Of Trustees Of The Leland Stanford Junior University	Methods for diagnosing and evaluating treatment of blood disorders
US20070248961A1 (en)	2006-04-20	2007-10-25	Maher Albitar	Methods for detecting mutations in JAK2 nucleic acid
EP2525651A4 (de) *	2010-01-22	2013-12-11	Chromatin Inc	Neue zentromere und verfahren zu ihrer anwendung

2004
- 2004-10-27 FR FR0411480A patent/FR2877013A1/fr active Pending
2005
- 2005-10-26 WO PCT/EP2005/055586 patent/WO2006045827A1/fr not_active Ceased
- 2005-10-26 AT AT05815749T patent/ATE382082T1/de active
- 2005-10-26 CA CA2754028A patent/CA2754028A1/fr not_active Abandoned
- 2005-10-26 CN CN2005800420223A patent/CN101072870B/zh not_active Expired - Lifetime
- 2005-10-26 DK DK05815749T patent/DK1692281T3/da active
- 2005-10-26 BR BRPI0517398A patent/BRPI0517398B8/pt active IP Right Grant
- 2005-10-26 JP JP2007538421A patent/JP5090171B2/ja not_active Expired - Lifetime
- 2005-10-26 KR KR1020077011851A patent/KR101203003B1/ko not_active Expired - Lifetime
- 2005-10-26 EP EP05815749A patent/EP1692281B8/de not_active Expired - Lifetime
- 2005-10-26 EP EP07118874A patent/EP1895000A1/de not_active Withdrawn
- 2005-10-26 CA CA2647086A patent/CA2647086C/fr not_active Expired - Lifetime
- 2005-10-26 CA CA2585062A patent/CA2585062C/fr not_active Expired - Lifetime
- 2005-10-26 AU AU2005298636A patent/AU2005298636B2/en not_active Expired
- 2005-10-26 US US10/580,458 patent/US7781199B2/en active Active
- 2005-10-26 SI SI200530129T patent/SI1692281T1/sl unknown
- 2005-10-26 PL PL05815749T patent/PL1692281T3/pl unknown
- 2005-10-26 ES ES05815749T patent/ES2296229T3/es not_active Expired - Lifetime
- 2005-10-26 MX MX2007005174A patent/MX2007005174A/es active IP Right Grant
- 2005-10-26 DE DE602005004008T patent/DE602005004008T2/de not_active Expired - Lifetime
- 2005-10-26 PT PT05815749T patent/PT1692281E/pt unknown
2007
- 2007-04-23 IL IL182761A patent/IL182761A0/en unknown
- 2007-04-26 ZA ZA200703433A patent/ZA200703433B/xx unknown
- 2007-11-02 US US11/934,359 patent/US7429456B2/en not_active Expired - Lifetime
2008
- 2008-09-19 US US12/234,616 patent/US8637235B2/en active Active
2009
- 2009-06-30 JP JP2009155912A patent/JP5290884B2/ja not_active Expired - Lifetime
2011
- 2011-08-19 US US13/213,841 patent/US8466338B2/en not_active Expired - Lifetime
2013
- 2013-01-11 JP JP2013003374A patent/JP6103691B2/ja not_active Expired - Lifetime
- 2013-02-15 US US13/768,709 patent/US8852931B2/en not_active Expired - Lifetime
2014
- 2014-01-27 US US14/164,880 patent/US10364430B2/en not_active Expired - Lifetime
2019
- 2019-05-29 US US16/424,976 patent/US10563200B2/en not_active Expired - Lifetime
2020
- 2020-01-06 US US16/734,854 patent/US11162100B2/en not_active Expired - Lifetime
2021
- 2021-09-29 US US17/488,839 patent/US20220042016A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US10563200B2 (en)	2020-02-18
JP5090171B2 (ja)	2012-12-05
AU2005298636B2 (en)	2009-11-26
CN101072870A (zh)	2007-11-14
US7429456B2 (en)	2008-09-30
EP1692281A1 (de)	2006-08-23
MX2007005174A (es)	2007-10-10
ES2296229T3 (es)	2008-04-16
JP5290884B2 (ja)	2013-09-18
JP2008517613A (ja)	2008-05-29
IL182761A0 (en)	2007-07-24
DE602005004008T2 (de)	2009-02-12
CA2585062C (fr)	2012-11-20
JP2013135673A (ja)	2013-07-11
CA2647086A1 (fr)	2006-05-04
US20120066776A1 (en)	2012-03-15
EP1692281B1 (de)	2007-12-26
HK1094974A1 (zh)	2007-04-20
BRPI0517398B1 (pt)	2021-03-02
ZA200703433B (en)	2008-08-27
US8637235B2 (en)	2014-01-28
DE602005004008D1 (de)	2008-02-07
US20130189683A1 (en)	2013-07-25
US20080076135A1 (en)	2008-03-27
US20090162849A1 (en)	2009-06-25
BRPI0517398A (pt)	2008-10-14
EP1895000A1 (de)	2008-03-05
KR20070104338A (ko)	2007-10-25
US20200140863A1 (en)	2020-05-07
US20150051263A2 (en)	2015-02-19
US20220042016A1 (en)	2022-02-10
DK1692281T3 (da)	2008-05-13
AU2005298636A1 (en)	2006-05-04
US20060288432A1 (en)	2006-12-21
CA2647086C (fr)	2012-09-18
KR101203003B1 (ko)	2012-11-21
JP2009278982A (ja)	2009-12-03
CA2585062A1 (fr)	2006-05-04
CA2754028A1 (fr)	2006-05-04
ATE382082T1 (de)	2008-01-15
PL1692281T3 (pl)	2008-06-30
PT1692281E (pt)	2008-02-06
EP1692281B8 (de)	2008-02-13
US7781199B2 (en)	2010-08-24
FR2877013A1 (fr)	2006-04-28
US8852931B2 (en)	2014-10-07
JP6103691B2 (ja)	2017-03-29
US20140249204A1 (en)	2014-09-04
US8466338B2 (en)	2013-06-18
US11162100B2 (en)	2021-11-02
US20190323007A1 (en)	2019-10-24
CN101072870B (zh)	2013-01-30
US10364430B2 (en)	2019-07-30
WO2006045827A1 (fr)	2006-05-04
SI1692281T1 (sl)	2008-04-30

Publication	Publication Date	Title
BRPI0517398B8 (pt)	2021-05-25	proteína isolada jak2, sequência nucleotídica, vetor de clonagem e/ou de expressão viral, sondas ou iniciadores, oligonucleotídeo, métodos ex vivo ou in vitro para determinar a presença ou a ausência da variante g1849t do gene jak2, anticorpo monoclonal, hibridoma, kit, sirna, processos in vitro permitindo determinar a inibição específica de jak2 v617f, de triagem, utilização de sirna, e, composição
Xu et al.	2014	MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis
Torregrosa-Muñumer et al.	2017	PrimPol is required for replication reinitiation after mtDNA damage
Wood et al.	2016	DNA polymerase θ (POLQ), double-strand break repair, and cancer
Yang et al.	2020	Aberrant expression of miR‐29b‐3p influences heart development and cardiomyocyte proliferation by targeting NOTCH2
Futai et al.	2013	Specific trans-synaptic interaction with inhibitory interneuronal neurexin underlies differential ability of neuroligins to induce functional inhibitory synapses
Xu et al.	2013	Tyrosylprotein sulfotransferase-1 and tyrosine sulfation of chemokine receptor 4 are induced by Epstein-Barr virus encoded latent membrane protein 1 and associated with the metastatic potential of human nasopharyngeal carcinoma
Lin et al.	2018	MicroRNA-128 inhibits proliferation and invasion of glioma cells by targeting COX-2
Shinchi et al.	2015	SUV420H2 suppresses breast cancer cell invasion through down regulation of the SH2 domain-containing focal adhesion protein tensin-3
JP2011511949A5 (de)	2012-03-29
Okura et al.	2014	Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model
Seubert et al.	2015	Tetraspanin CD 63 acts as a pro‐metastatic factor via β‐catenin stabilization
CN105980555A (zh)	2016-09-28	作为胃癌的责任因子的新型融合基因
Stapelberg et al.	2014	Indoleamine-2, 3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans
Sharma et al.	2021	Human telomerase is directly regulated by non-telomeric TRF2-G-quadruplex interaction
Li et al.	2020	Ubiquitin carboxyl‐terminal hydrolase L1 promotes hypoxia‐inducible factor 1‐dependent tumor cell malignancy in spheroid models
Akbari et al.	2007	Different organization of base excision repair of uracil in DNA in nuclei and mitochondria and selective upregulation of mitochondrial uracil-DNA glycosylase after oxidative stress
Rebollo et al.	2017	ESM-1 siRNA knockdown decreased migration and expression of CXCL3 in prostate cancer cells
KR20180044617A (ko)	2018-05-03	Uhrf1 및 dnmt1을 포함하는 세포 노화 진단용 바이오마커 조성물
Pal et al.	2015	Augmented telomerase activity, reduced telomere length and the presence of alternative lengthening of telomere in renal cell carcinoma: plausible predictive and diagnostic markers
CN109069513A (zh)	2018-12-21	用于治疗或预防肝癌的组合物
Zhou et al.	2019	A conformational switch-based fluorescent biosensor for homogeneous detection of telomerase activity
Xi et al.	2014	A natural antisense transcript regulates acetylcholinesterase gene expression via epigenetic modification in Hepatocellular Carcinoma
Kim et al.	2022	DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling
Jubelin et al.	2024	Identification of MCM4 and PRKDC as new regulators of osteosarcoma cell dormancy based on 3D cell cultures

Legal Events

Date	Code	Title	Description
2012-03-20	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2015-12-22	B15K	Others concerning applications: alteration of classification	Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/12 , C12Q 1/68 , G01N 33/53 Ipc: C12N 9/12 (2006.01), C12Q 1/68 (2006.01), G01N 33/
2018-03-20	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-01-28	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-02-18	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-06-16	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2020-08-04	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-12-01	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-02-02	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-03-02	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2023-05-16	B25A	Requested transfer of rights approved	Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES (FR) ; INSTITUT GUSTAVE-ROUSSY (FR) ; UNIVERSITE PARIS-SACLAY (FR)